Compare OMEX & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | LUCD |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 132.4M |
| IPO Year | N/A | 2021 |
| Metric | OMEX | LUCD |
|---|---|---|
| Price | $2.15 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | 1.0M | ★ 2.3M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $467,122.00 | ★ $4,399,000.00 |
| Revenue This Year | N/A | $7.69 |
| Revenue Next Year | N/A | $155.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.01 |
| 52 Week Low | $0.27 | $0.82 |
| 52 Week High | $4.43 | $1.80 |
| Indicator | OMEX | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 57.02 |
| Support Level | $1.99 | $1.05 |
| Resistance Level | $2.67 | $1.63 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 28.10 | 31.07 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. The company provides specialized mineral exploration, project development, and marine services to clients. It is engaged in the discovery, validation, and development of subsea mineral deposits in a socially and environmentally responsible manner. The company works with governments to identify mineral resources in Exclusive Economic Zones, focusing on phosphorite (fertilizer) and polymetallic nodules (battery metals) projects. Its projects include the ExO Phosphate project, CIC, Ocean Minerals, and the LIHIR Gold project.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.